Systemic Combining Inflammatory Score (SCIS): a New Score for Prediction of Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer

Background: An accurate and early diagnosis of bladder cancer (BC) is essential to offer patients the most appropriate treatment and the highest cure rate. For this reason, patients need to be best stratified by class and risk factors. We aimed to develop a score able to better predict cancer outcomes, using serum variables of inflammation.

Methods: A total of 1,510 high-risk non-muscle invasive bladder cancer (NMIBC) patients were included in this retrospective observational study. Patients with pathologically proven T1 HG/G3 at first TURBT were included. Systemic combined inflammatory score (SCIS) was calculated according to systemic inflammatory markers (SIM), modified Glasgow prognostic score (mGPS), and prognostic nutritional index (PNI) dichotomized (final score from 0 to 3).

Results: After 48 months of follow-up (IQR 40.0-73.0), 727 patients recurred (48.1%), 485 progressed (32.1%), 81 died for cancer (7.0%), and 163 died for overall causes (10.8%). Overall, 231 (15.3%) patients had concomitant Cis, 669 (44.3%) patients had multifocal pathology, 967 (64.1%) patients had tumor size >3 cm. Overall, 357 (23.6%) patients received immediate-intravesical therapy, 1,356 (89.8%) received adjuvant intravesical therapy, of which 1,382 (91.5%) received BCG, 266 (17.6%) patients received mitomycin C, 4 (0.5%) patients received others intravesical therapy. Higher SCIS was independently predictive of recurrence (hazard ratio HR 1.5, 1.3 and 2.2) and cancer specific mortality for SCIS 0 and 3 (HR: 1.61 and 2.3), and overall mortality for SCIS 0 and 3 (HR: 2.4 and 3.2). Conversely, SCIS was not associated with a higher probability of progression.

Conclusions: The inclusion of the SCIS in clinical practice is simple to apply and can help improve the prediction of cancer outcomes. It can identify patients with high-grade BC who are more likely to experience disease mortality.

Citing Articles

Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette-Guérin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer.

Lee J, Yoo S, Choo M, Cho M, Son H, Jeong H Diagnostics (Basel). 2023; 13(19).

PMID: 37835857 PMC: 10572862. DOI: 10.3390/diagnostics13193114.

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.

Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pohlmann J, Pollock R Front Oncol. 2023; 13:1170124.

PMID: 37333804 PMC: 10272547. DOI: 10.3389/fonc.2023.1170124.

Comparison of different prediction tools for the risk of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a propensity-matched analysis.

Luo Z, Jiao B, Zhao H, Huang T, Liu Y, Chen H Clin Transl Oncol. 2023; 26(1):136-146.

PMID: 37273148 DOI: 10.1007/s12094-023-03226-1.

A prognostic model for bladder cancer based on cytoskeleton-related genes.

Peng C, Guo S, Yang Z, Li X, Su Q, Mo W Medicine (Baltimore). 2023; 102(17):e33538.

PMID: 37115085 PMC: 10146030. DOI: 10.1097/MD.0000000000033538.

MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.

Lucarelli G, Netti G, Rutigliano M, Lasorsa F, Loizzo D, Milella M Int J Mol Sci. 2023; 24(5).

PMID: 36902242 PMC: 10003656. DOI: 10.3390/ijms24054814.

References

Kimura S, D Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei M . Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Urol Oncol. 2018; 37(3):179.e19-179.e28. DOI: 10.1016/j.urolonc.2018.11.005. View

Ferro M, Vartolomei M, Russo G, Cantiello F, Abu Farhan A, Terracciano D . An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 2018; 37(3):507-514. DOI: 10.1007/s00345-018-2397-1. View

Ding J, Yao K, Wang P, Yan C . Clinical significance of prognostic nutritional index in patients with glioblastomas. Medicine (Baltimore). 2018; 97(48):e13218. PMC: 6283194. DOI: 10.1097/MD.0000000000013218. View

Choi K, Hong S, Chang Y, Lee W, Lee B, Paik I . Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014; 86(6):309-13. PMC: 4062449. DOI: 10.4174/astr.2014.86.6.309. View

Vartolomei M, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R . Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018; 16(6):445-452. DOI: 10.1016/j.clgc.2018.07.003. View

Mariappan P, Smith G . A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol. 2005; 173(4):1108-11. DOI: 10.1097/01.ju.0000149163.08521.69. View

Cui J, Chen S, Bo Q, Wang S, Zhang N, Yu M . Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ. Onco Targets Ther. 2017; 10:5541-5550. PMC: 5702160. DOI: 10.2147/OTT.S146990. View

Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Hiwatashi K . Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Pancreatology. 2015; 15(6):688-93. DOI: 10.1016/j.pan.2015.09.015. View

Jobczyk M, Stawiski K, Fendler W, Rozanski W . Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis. Cancer Med. 2020; 9(11):4014-4025. PMC: 7286464. DOI: 10.1002/cam4.3007. View

10.

Arnson Y, Shoenfeld Y, Amital H . Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010; 34(3):J258-65. DOI: 10.1016/j.jaut.2009.12.003. View

11.

Ferro M, Di Lorenzo G, Buonerba C, Lucarelli G, Russo G, Cantiello F . Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. J Cancer. 2018; 9(22):4250-4254. PMC: 6277616. DOI: 10.7150/jca.26129. View

12.

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M . Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009; 182(5):2195-203. DOI: 10.1016/j.juro.2009.07.016. View

13.

Ferro M, Di Lorenzo G, Vartolomei M, Bruzzese D, Cantiello F, Lucarelli G . Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. World J Urol. 2019; 38(1):143-150. DOI: 10.1007/s00345-019-02754-2. View

14.

Rieken M, Shariat S, Kluth L, Crivelli J, Abufaraj M, Foerster B . Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol. 2017; 36(1):8.e17-8.e24. PMC: 7675223. DOI: 10.1016/j.urolonc.2017.08.027. View

15.

Ogihara K, Kikuchi E, Yuge K, Yanai Y, Matsumoto K, Miyajima A . The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking. Ann Surg Oncol. 2016; 23(Suppl 5):1039-1047. DOI: 10.1245/s10434-016-5578-4. View

16.

Forrest L, McMillan D, McArdle C, Angerson W, Dunlop D . Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6):1028-30. PMC: 2376960. DOI: 10.1038/sj.bjc.6601242. View

17.

Leitch E, Chakrabarti M, Crozier J, McKee R, Anderson J, Horgan P . Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97(9):1266-70. PMC: 2360467. DOI: 10.1038/sj.bjc.6604027. View

18.

Campi R, Seisen T, Roupret M . Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018; 4(4):472-480. DOI: 10.1016/j.euf.2018.08.010. View

19.

Crumley A, McMillan D, McKernan M, McDonald A, Stuart R . Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006; 94(5):637-41. PMC: 2361199. DOI: 10.1038/sj.bjc.6602998. View

20.

Wang Z, Wang Y, Zhang X, Zhang T . Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysis. Clin Chim Acta. 2018; 486:303-310. DOI: 10.1016/j.cca.2018.08.030. View